 Home > Medical News > Latest Medical News > Yingli Pharmaceutical's PI3Kδ inhibitor has obtained three FDA orphan drug qualifications

Yingli Pharmaceutical's PI3Kδ inhibitor has obtained three FDA orphan drug qualifications

 Last Update: 2021-06-05
 Source: Internet
 Author: User

Tags

new silver

medical medium hpv

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Article source: Pharmaceutical Guanlan

On May 28, Yingli Pharmaceuticals announced that the US FDA officially granted its PI3Kδ inhibitor linpris tablets (YY-20394) a new orphan drug designation for the treatment of patients with T-cell lymphoma.

The PI3K signaling pathway plays an important role in regulating cell growth, movement, survival, metabolism and angiogenesis.

Limpris is a new generation PI3Kδ (phosphatidylinositol 3-kinase subtype δ) highly selective inhibitor independently developed by Yingli Pharmaceutical.

In China, the application of linpril for the treatment of relapsed and/or refractory follicular lymphoma has been included in the breakthrough treatment category.

At present, Limpris has also carried out a number of clinical trials in the United States, and has shown significant efficacy and good safety.

This time the FDA granted orphan drug designation again, which is another important research progress made by Limprizol in the United States.

Note: The original text has been deleted

Reference materials:

[1]New progress|Yingli Pharmaceutical Limpris tablets (YY-20394) obtained another FDA orphan drug qualification.

[2] Yingli Pharmaceutical's application for Limpris tablets was accepted by the National Medical Products Administration.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.